| pubmed-article:11093159 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0019733 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0003316 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0205246 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:11093159 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:11093159 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:11093159 | pubmed:dateCreated | 2001-1-25 | lld:pubmed |
| pubmed-article:11093159 | pubmed:abstractText | Low-affinity MHC class I-associated cryptic epitopes derived from self proteins overexpressed in a wide variety of human tumors or derived from antigens of viruses exhibiting a high mutation rate, could be interesting candidates for tumor and virus immunotherapy, respectively. However, identification of low-affinity MHC-associated epitopes comes up against their poor immunogenicity. Here we describe an approach that enhances immunogenicity of nonimmunogenic low-affinity HLA-A2.1-binding peptides. It consists of modifying their sequence by introducing a tyrosine in the first position (P1Y). P1Y substitution enhances affinity of HLA-A2.1-associated peptides without altering their antigenic specificity. In fact, P1Y variants of ten nonimmunogenic low-affinity peptides exhibited a 2.3- to 55-fold higher binding affinity and/or stabilized the HLA-A2.1 for at least 2 h more than the corresponding native peptides. More importantly, P1Y variants efficiently triggered in vivo native peptide-specific CTL which also recognized the corresponding naturally processed epitope. The possibility for generating CTL against any low-affinity HLA-A2.1-associated peptide provides us with the necessary tool for the identification of cryptic tumor and virus epitopes which could be used for peptide-based immunotherapy. | lld:pubmed |
| pubmed-article:11093159 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11093159 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11093159 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11093159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11093159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11093159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11093159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11093159 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11093159 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11093159 | pubmed:issn | 0014-2980 | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:GrossD ADA | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:CordopatisPP | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:Kosmatopoulos... | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:PascoloSS | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:LemonnierF... | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:ScardinoAA | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:TourdotSS | lld:pubmed |
| pubmed-article:11093159 | pubmed:author | pubmed-author:SaloustrouEE | lld:pubmed |
| pubmed-article:11093159 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11093159 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:11093159 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11093159 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11093159 | pubmed:pagination | 3411-21 | lld:pubmed |
| pubmed-article:11093159 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:meshHeading | pubmed-meshheading:11093159... | lld:pubmed |
| pubmed-article:11093159 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11093159 | pubmed:articleTitle | A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. | lld:pubmed |
| pubmed-article:11093159 | pubmed:affiliation | INSERM 487, Villejuif, France. | lld:pubmed |
| pubmed-article:11093159 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11093159 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11093159 | lld:pubmed |
